• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Intersect ENT reports Q4, full-year revenue prelims

January 8, 2018 By Sarah Faulkner

Intersect ENTShares in Intersect ENT (NSDQ:XENT) held steady today after the company reported preliminary data for its fourth quarter and full-year revenues.

The Menlo Park, Calif.-based company said it expects to reel in $96.1 – $96.3 million in revenue for the full year of 2017, up 22% from 2016. Intersect also pegged its fourth-quarter revenue between $29.3 million and $29.5 million, up 21% compared to the same period last year.

In December, the company’s Sinuva steroid-eluting implant won FDA approval as a treatment for recurrent nasal polyp disease in patients who have previously undergone ethmoid sinus surgery.

Intersect reported today that it expects to launch Sinuva commercially in the second quarter of 2018. The company forecasts full-year revenue for 2018 to be between $111 and $116 million – 8% of which will come from Sinuva sales.

“We view XENT’s 4Q rev. outperformance and initial 2018 guidance – likely conservative in our view – as encouraging signs ahead of one of the biggest new product cycles (Sinuva) in the company’s history on tap in 2Q18. We continue to view XENT as an exciting small-cap growth story with an 80%+ GM profile, and now with Sinuva approved we have increased confidence in the company’s ability to drive meaningfully higher sales momentum in 2018 & beyond,” Leerink analysts Richard Newitter and Jaime Morgan wrote in a note to investors.

Beyond its preliminary financials, Intersect announced today that it finished enrolling a 50-person trial that is slated to evaluate the safety of repeat placement of the Sinuva implant in chronic sinusitis patients with nasal polyps.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Implants, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Intersect ENT Inc.

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS